3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength
3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...
Finanical Reports
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released...
Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded...
R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...
CSPC Pharmaceutical Group Reports Moderate H1 2024 Revenue Growth with Patent Medicines Driving the Increase
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical enterprise, has announced its financial...
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi...
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its...
CSPC Pharmaceutical Group Reports Modest Gains in H1 2024 with Patent Medicines Driving Revenue
HONG KONG—CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced its financial results for the first...
CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...
RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales
RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving...
Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%
Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...
Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...
Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...
Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...